Era Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 23-09-2024
- Paid Up Capital ₹ 0.10 M
as on 23-09-2024
- Company Age 20 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 12.00%
(FY 2023)
- Profit 503.31%
(FY 2023)
- Ebitda 334.67%
(FY 2023)
- Net Worth 22.31%
(FY 2023)
- Total Assets 9.77%
(FY 2023)
About Era Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Promila Bhusari, Ashokkumar Bhusari, Rita Khanna, and One other member serve as directors at the Company.
- CIN/LLPIN
U51397MH2004PTC145860
- Company No.
145860
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
22 Apr 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Era Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ashokkumar Bhusari  | Managing Director | 22-Apr-2004 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Promila Bhusari | Director | 22-Apr-2004 | Current |
Rita Khanna  | Director | 22-Apr-2004 | Current |
| Chander Khanna | Director | 22-Apr-2004 | Current |
Financial Performance of Era Pharmaceuticals.
Era Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 12% increase. The company also saw a substantial improvement in profitability, with a 503.31% increase in profit. The company's net worth Soared by an impressive increase of 22.31%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Era Pharmaceuticals?
Unlock access to Era Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Zifam Pinnacle Healthcare Private LimitedActive 14 years 11 monthsRita Khanna and Chander Khanna are mutual person
- Delta Biopharma Private LimitedActive 12 years 13 days
Rita Khanna and Chander Khanna are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Era Pharmaceuticals?
Unlock and access historical data on people associated with Era Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Era Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Era Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
